PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis
- Conditions
- Lyme Borreliosis
- Interventions
- Biological: VLA15Biological: Placebo
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 246
- Registration Number
- NCT03970733
- Locations
- ๐บ๐ธ
Clinical Research Consulting, LLC, Milford, Connecticut, United States
๐บ๐ธStamford Therapeutics Consortium, Stamford, Connecticut, United States
๐บ๐ธUnited Medical Associates, Binghamton, New York, United States
A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 164
- Registration Number
- NCT03969719
- Locations
- ๐จ๐ฆ
The Western Centre for Functional and Metabolic Mapping, London, Ontario, Canada
๐บ๐ธHope Clinical Research, Canoga Park, California, United States
๐บ๐ธeStudySite, La Mesa, California, United States
Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7308
- Registration Number
- NCT03964649
- Locations
- ๐บ๐ธ
Pfizer, New York, New York, United States
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 219
- Registration Number
- NCT03963401
- Locations
- ๐ต๐ฑ
RCMed Oddzial Sochaczew, Sochaczew, Poland
๐ต๐ฑZespol Poradni Specjalistycznych "REUMED" Filia nr 2, Lublin, Poland
๐ฆ๐บEmeritus Research, Melbourne, Victoria, Australia
Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants
- Conditions
- AdultDrug InteractionsHealthy VolunteersHumans
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT03961997
- Locations
- ๐ง๐ช
Brussels Clinical Research Unit, Brussels, Be-bru, Belgium
Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged โฅ2 Years With Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 81
- Registration Number
- NCT03954158
- Locations
- ๐ฏ๐ต
Fukuwa Clinic, Chuo-ku, Tokyo, Japan
๐ฏ๐ตSekino Hospital, Toshima-ku, Tokyo, Japan
๐ฏ๐ตMedical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 778
- Registration Number
- NCT03950232
- Locations
- ๐ง๐ช
AZ Delta Roeselare VZW Campus, Roeselare, Belgium
๐ซ๐ทCHU Nantes - Hรดtel Dieu, Nantes, France
๐ฉ๐ชKrankenhaus Waldfriede e.V.,, Berlin, Germany
Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
- Conditions
- Sickle Cell Disease
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Pfizer
- Registration Number
- NCT03943615
- Locations
- ๐บ๐ธ
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
๐บ๐ธUniversity of South Alabama, Mobile, Alabama, United States
๐บ๐ธThe John Hopkins Hospital, Baltimore, Maryland, United States
Trial for Treatment Refractory Trigeminal Neuralgia
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 65
- Registration Number
- NCT03941834
- Locations
- ๐บ๐ธ
Center for Neurohealth DBA Kaizen Brain Center, La Jolla, California, United States
๐บ๐ธImaging Clinic at Stanford Neuroscience Health Center, Palo Alto, California, United States
๐บ๐ธStanford Neuroscience Health Center- SNHC Pharmacy, Palo Alto, California, United States
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 189
- Registration Number
- NCT03938792
- Locations
- ๐บ๐ธ
USF Health Morsani Center For Advanced Healthcare, Tampa, Florida, United States
๐บ๐ธUniversity of Iowa, Iowa City, Iowa, United States
๐บ๐ธNorthwell Health HTC, New Hyde Park, New York, United States